Skip to main content

Table 1 Difference in patient characteristics between the TPF and PF groups in the observational and propensity-matched datasets

From: Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis

Characteristic Observational dataset [cases (%)] Propensity score-matched dataset [cases (%)]
TPF PF P TPF PF P
Total 315 (25.1) 941 (74.9)   294 (50.0) 294 (50.0)  
Number of DSS events 31 (9.8) 228 (24.2)   28 (9.5) 55 (18.7)  
Gender    0.649    0.114
 Male 235 (74.6) 715 (76.0)   224 (76.2) 206 (70.1)  
 Female 80 (25.4) 226 (24.0)   70 (23.8) 88 (29.9)  
Age    0.147    0.740
 ≤ 45 172 (54.6) 558 (59.3)   162 (55.1) 167 (56.8)  
 > 45 143 (45.4) 383 (40.7)   132 (44.9) 127 (43.2)  
Histology    0.376    0.362
 I 0 (0) 3 (0.3)   0 (0) 2 (0.7)  
 II 18 (5.7) 41 (4.4)   18 (6.1) 17 (5.8)  
 III 297 (94.3) 897 (95.3)   276 (93.9) 275 (93.5)  
T stage    0.192    0.485
 T1 13 (4.1) 22 (2.3)   9 (3.1) 4 (1.4)  
 T2 36 (11.4) 126 (13.4)   32 (10.9) 28 (9.5)  
 T3 157 (49.9) 436 (46.3)   153 (52.0) 162 (55.1)  
 T4 109 (34.6) 357 (38.0)   100 (34.0) 100 (34.0)  
N stage    0.364    0.377
 N0 25 (7.9) 103 (10.9)   25 (8.5) 33 (11.2)  
 N1 93 (29.5) 276 (29.3)   85 (28.9) 89 (30.3)  
 N2 141 (44.8) 420 (44.7)   133 (45.2) 134 (44.6)  
 N3 56 (17.8) 142 (15.1)   51 (17.4) 38 (12.9)  
Clinical stage    0.649    0.456
 III 165 (52.4) 478 (50.8)   157 (53.4) 167 (56.9)  
 IV 150 (47.6) 463 (49.2)   137 (46.6) 127 (43.1)  
KPS    0.837    0.176
 70–80 7 (2.2) 25 (2.7)   7 (2.4) 2 (0.7)  
 ≥ 90 308 (97.8) 916 (97.3)   287 (97.6) 292 (99.3)  
Smoking    0.086    0.144
 Yes 119 (37.8) 409 (43.5)   115 (39.1) 97 (33.0)  
 No 196 (62.2) 532 (56.5)   179 (60.9) 197 (67.0)  
BMI    0.638    0.602
 < 19 33 (10.5) 96 (10.2)   31 (10.6) 29 (9.9)  
 19–24 200 (63.5) 574 (61.0)   185 (62.9) 176 (59.8)  
 > 24 82 (26.0) 271 (28.8)   78 (26.5) 89 (30.3)  
CDDP dose (mg/m2)    0.741    0.438
 < 200  188 (59.7) 551 (58.6)   185 (62.9) 195 (66.3)  
 ≥ 200  127 (40.3) 390 (41.4)   109 (37.1) 99 (33.7)  
Number of IC cycles    0.169    0.729
 < 2 54 (17.1) 131 (13.9)   46 (15.7) 42 (14.3)  
 ≥ 2 261 (82.9) 810 (86.1)   248 (84.3) 252 (85.7)  
Radiation technique    < 0.001    1.0
 IMRT 263 (83.5) 262 (27.9)   242 (82.3) 242 (82.3)  
 2D-CRT 52 (16.5) 679 (72.1)   52 (17.7) 52 (17.7)  
  1. TPF taxane, cisplatin and 5-fluorouracil, PF cisplatin and 5-fluorouracil, DSS disease-specific survival, KPS Karnofsky Performance Status, BMI body mass index, IMRT intensity-modulated radiotherapy, 2D-CRT two-dimensional radiotherapy